Cytoo Announces Venture Partnership with PharmaNest to Launch 2D+ in the USA
CYTOO Inc,the US subsidiary of CYTOO SA, is pleased to announce a partnership with PharmaNest, a contract operations organization who commercializes breakthrough International IND-Enabling Technologies and Services for the US Markets.
PRINCETON, NJ (I-Newswire) April 4, 2012 - CYTOO Inc, the US subsidiary of CYTOO SA, FRANCE, is pleased to announce a partnership with PharmaNest, Princeton, NJ, a contract operations organization who commercializes breakthrough International IND-Enabling Technologies and Services for the US Markets.
CYTOO develops products for cellular analysis and high-content cell screening. CYTOO’s innovative 2D+ Cell Culture Platform is based on the use of micro-patterns on plates to enable major improvements in culturing cells. 2D+ increases assay reproducibility/reliability and improves the capacity to achieve a more physiological phenotype in cells cultured on 2D surfaces without resorting to a 3D culture system.
PharmaNest’s experienced team is joining the CYTOO Inc team to provide larger visibility of the 2D+ Technology in North America and gather business efforts.
“2D+ is a new Dimension in Cell cultures and offers innovative options for Assay Optimization, Assay resuscitation (for instance, if you want to increase the Z’ of an existing assay or reduce the consumption of precious and expensive cells). Importantly, it offers revolutionary means to quantify and/or drive the behavior of cells to enable new cell assays. The challenge of the commercialization of such innovative solutions is at the heart of what PharmaNest does well.” said Matt Petitjean, Ph.D and President of PharmaNest.
“We are looking forward to increase our scientific visibility among the Pharmaceutical Industry while partnering with PharmaNest experts. Their scientific expertise and market knowledge are great added-values to our development in North America” said Pauline Menager, PhD Manager of Scientific Affairs at CYTOO.
About CYTOO
CYTOO focuses on innovative products for the life science research market with an emphasis in cell based assays, high content analysis and cell screening. The company has tailored a portfolio of innovative products using its proprietary cell adhesive micro-pattern technologies to target first its fast growing High Content Screening and Analysis segment within the large cell biology market.
www.cytoo.com
Additional Resources
About PHARMANEST
PharmaNest commercializes breakthrough International IND-Enabling Technologies and Services for the More..US Markets. PharmaNest's business model and highly experienced team empower early stage companies to play in high growth market segments, at a fraction of the cost of alternative solutions.Less..
Contact Information
PHARMANEST
Press Contact
100 Overlook Center, Princeton, NJ
08540
Phone : 609 375 2349
Published On:
April 4, 2012Print Release:
Print ReleaseIf you have questions regarding information in this press release contact the company listed above. I-Newswire.com is a press release service and not the author of this press release.The information that is on or available through this site is for informational purposes only and speaks only as of the particular date or dates of that information. As some companies and PR Agencies submit their press releases once per week,month or quarter, make sure to check the official company website for accurate release dates as our site displays the I-Newswire.com press release distribution date only.We do not guarantee the accuracy or completeness of information on or available through this site, and we are not responsible for or omissions in that information or for actions taken in reliance on that information.
